Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric tildrakizumab trial in moderate to severe chronic plaque psoriasis
2019-003551-11Phase 2Active
- Sponsor
- Sun Pharma Advanced Research Company
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tildrakizumab in psoriasis (3 arms), sponsored by Sun Pharma Advanced Research Company. Primary endpoints: PASI 75 response rate at Week 12 and Physician's Global Assessment response at Week 12. Started Jun 2020; status: active.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2019-003551-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003551-11.